연구성과로 돌아가기

2024 연구성과별 연구자 정보 (113 / 2344)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Omori, Takeshi Omori, T 12 Osaka Int Canc Inst, Dept Gastroenterol Surg, Osaka, Japan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Rha, Sun Young Rha, SY 13 Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea 0000-0002-2512-4531 Rha, Sun Young msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Kim, Tae Yong Kim, TY 14 Seoul Natl Univ Hosp, Oncol Dept, Seoul, South Korea msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Ryu, Keun Won Ryu, KW 15 Natl Canc Ctr, Ctr Gastr Canc, Surg Dept, Goyang, South Korea msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Sakuramoto, Shinichi Sakuramoto, S 16 Saitama Med Univ, Int Med Ctr, Dept Gastrointestinal Surg, Saitama, Japan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Nishida, Yasunori Nishida, Y 17 Keiyukai Sapporo Hosp, Dept Gastrointestinal Surg & Med Oncol, Sapporo, Japan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Fukushima, Norimasa Fukushima, N 18 Yamagata Prefectural Cent Hosp, Dept Surg, Yamagata, Japan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Yamada, Takanobu Yamada, T 19 Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Japan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Bai, Li-Yuan Bai, LY 20 China Med Univ, China Med Univ Hosp, Div Hematol & Oncol, Taichung, Taiwan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Hirashima, Yoshinori Hirashima, Y 21 Ono Pharmaceut, Osaka, Japan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Hagihara, Shunsuke Hagihara, S 22 China Med Univ, China Med Univ Hosp, Div Hematol & Oncol, Taichung, Taiwan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Nakada, Takashi Nakada, T 23 China Med Univ, China Med Univ Hosp, Div Hematol & Oncol, Taichung, Taiwan msasako2010@yahoo.co.jp;
Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Sasako, Mitsuru Sasako, M 24 교신저자 Yodogawa Christians Hosp, Dept Surg, Osaka 5330024, Japan msasako2010@yahoo.co.jp;
Adsorption of perfluorosulfonic acids (PFSAs) on an ultrafine potato peel waste grafted β-cyclodextrin (UFPPW-β-CD) Bruckmann, Franciele da Silva Bruckmann, FD 1 Univ Fed Santa Maria, Res Grp Adsorpt & Catalyt Proc Engn ENGEPAC, Ave Roraima 1000-7, BR-97105900 Santa Maria, RS, Brazil IQR-8487-2023 Bruckmann, Franciele 0000-0002-9800-1057 Bruckmann, Franciele sonia.jemli@fss.usf.tn;lfsoacademico@gmail.com;guilherme_dotto@yahoo.com.br;
Adsorption of perfluorosulfonic acids (PFSAs) on an ultrafine potato peel waste grafted β-cyclodextrin (UFPPW-β-CD) Jemli, Sonia Jemli, S 2 교신저자 Univ Sfax, Ctr Biotechnol Sfax, Lab Microbial & Enzymat Biotechnol & Biomol LBMEB, POB 1177, Sfax 3018, Tunisia sonia.jemli@fss.usf.tn;lfsoacademico@gmail.com;guilherme_dotto@yahoo.com.br;
페이지 이동: